There are 2789 resources available
267P - Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) + entinostat (entino) in MORPHEUS-HR+ breast cancer (M-HR+BC)
Presenter: Amir Sonnenblick
Session: ePoster Display
270P - Phase Ib study of venadaparib, a potent and selective PARP inhibitor, in homologous recombination repair (HRR) mutated breast cancer
Presenter: Seock-Ah Im
Session: ePoster Display
271P - First-in-human, phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumors
Presenter: Ye Guo
Session: ePoster Display
272P - Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)
Presenter: Miguel Martin
Session: ePoster Display
109P - A novel, comprehensive glimpse at NY-ESO-1 expression, mRNA to protein translation, & potential impact on clinical studies
Presenter: Kristin Blouch
Session: ePoster Display
110P - Novel genetic variants of CBS and COMT in the transsulfuration pathway genes are associated with survival of non-small cell lung cancer patients
Presenter: Yufeng Wu
Session: ePoster Display
111P - A study on the relationship between tumor fusion burden (TFB) and tumor immune microenvironment
Presenter: xiaoyu Liu
Session: ePoster Display
112P - Prognostic impact of five serum biomarkers in patients with advanced non-small cell lung cancer (NSCLC): An exploratory analysis
Presenter: Yomna Nassar
Session: ePoster Display
276P - Dalpiciclib, a novel CDK4/6 inhibitor, combined with pyrotinib for HER2+ advanced breast cancer: Interim results of a phase II trial
Presenter: Min Yan
Session: ePoster Display